Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter, Open-Label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects With Relapsed or Refractory B-cell Malignancies.

NCT04775745 is registered in ClinicalTrials.gov with Newave Pharmaceutical Inc as lead sponsor.

NCT NCT04775745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04775745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter, Open-Label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects With Relapsed or Refractory B-cell Malignancies.
Lead sponsor
Newave Pharmaceutical Inc
Phase
Phase 1
Overall status
Recruiting
Start date
July 19, 2021
Completion date
December 31, 2027
Enrollment
60 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cll/sll, diffuse large b cell lymphoma, follicular lymphoma, hairy cell leukemia, mantle cell lymphoma, marginal zone lymphoma, waldenstrom macroglobulinemia